○Jun Tsukimoto¹, Yuto Horii¹, Toshiki Iniwa¹, So-ichiro Nishioka¹, Kohji Itoh¹ (1. Grad.Sch.Pharm. Sci., Tokushima Univ.)

○Chihiro Katsumata¹, Akira Minami¹, Jyun Goto¹, Mako Shiratori¹, Hiroaki Kanazawa², Takashi Suzuki¹ (1. Sch. of Pharmaceu. Sci., Univ. of Shizuoka, 2. Sch. of Nursing. Sci., Univ. of Shizuoka)

○Masumi Nagata¹, Shuji Mizumoto¹, Daiki Endo¹, Shuhei Yamada¹ (1. Facult. Pharm., Meijo Univ.)

○Shintaro Onishi^1,2, Yuki Kurebayashi², Takuya Mori¹, Noriyasu Ota¹, Tadanobu Takahashi², Takashi Suzuki² (1. Kao corp., 2. Univ. of Shizuoka.)

○Shuji Mizumoto^1,2, Andreas R. Janecke³, Azita Sadeghpour⁴, Gundula Povysil⁵, Marie T. McDonald⁵, Sheila Unger⁶, Susanne Greber-Platzer⁷, Nicholas Katsanis⁴, Andrea Superti-Furga⁶, Kazuyuki Sugahara¹, Erica E. Davis⁴, Shuhei Yamada¹, Julia Vodopiutz⁷ (1. Facult. Pharm., Meijo Univ., 2. Dunedin Sch. Med., Univ. Otago, New Zealand, 3. Med. Univ. Innsbruck, Austria, 4. Duke Univ. Med. Center, U.S.A., 5. Johannes Kepler Univ., Austria, 6. Univ. Lausanne, Switzerland, 7. Med. Univ. Vienna, Austria)

○Yuu Miyazaki¹, Atsuhiko Ichimura¹, Ryo Kitayama¹, Masato Tsujimoto¹, Daiju Yamazaki², Miyuki Nishi¹, Hiroshi Takeshima¹ (1. Grad. Sch. Pharm. Sci., Kyoto Univ., 2. NIHS)

○Ryuzaburo Yuki^1,2,3, Noritaka Yamaguchi¹, Takashi Tatewaki¹, Ichiro Manabe², Naoto Yamaguchi¹ (1. Grad. Sch. Pharm. Sci., Chiba Univ., 2. Grad. Sch. Med., Chiba Univ., 3. Kyoto Pharm. Univ.)

○Takayuki Suzuki¹, Mituki Ando¹, Naoto Hori¹, Ryota Inoue¹, Yuki Takakura¹, Aki Akatu¹, Takuya Honda^1,3, Noritaka Yamaguchi^1,2, Naoto Yamaguchi¹ (1. Lab.of Mol.Cell Biol.,Grad.Sch.of Pharm.Sci.,Chiba Univ., 2. Dept. of Mol.Cardiovasc.Pharm.,Grad.Sch.of Pharm.Sci.,Chiba Univ., 3. Lab.of Chemical Pharmacology.,Grad.Sch.of Pharm.Sci.,Chiba Univ.)

○Naoto Hori¹, Kazuyuki Okada¹, Yuki Takakura¹, Kensuke Hirata¹, Moeka Machida¹, Ayumi Sugino¹, Naoto Hirai¹, Hiroyuki Takano², Naoto Yamaguchi¹, Noritaka Yamaguchi^1,2 (1. Lab. of Mol. Cell Biol., Grad. Sch. of Pharm. Sci., Chiba Univ., 2. Dept. of Mol. Cardiovasc. Pharm., Grad. Sch. of Pharm. Sci., Chiba Univ.)

○TAITO NISHINO¹, AYAKO AIHARA¹, HIROYUKI NAKAJIMA¹, NATSUKI FUKAZAWA¹, KEIICHIROU OOTSUKA¹, IWAWAKI TAKUMI¹, KOICHIROU SARUHASHI¹, TAKUMI MIKASHIMA¹ (1. Nissan Chem. Corp.)

○Yuya Nagaoka¹, Erika Ishihara¹, Nishina Hiroshi¹ (1. Department of Developmental and Regenerative Biology Medical Research Institute Tokyo Medical and Dental University)

○Kana Shimizu^1,2, Yoichi Sunagawa^1,2,3, Masafumi Funamoto^1,2, Yasufumi Katanasaka^1,2,3, Yusuke Miyazaki^1,2,3, Hiroki Honda¹, Yoshiki Kawakami¹, Nurmila Sari¹, Satoshi Shimizu^1,2, Hiromichi Wada², Koji Hasegawa^1,2, Tatsuya Morimoto^1,2,3 (1. Grad. Sch. Integ. Pharm. Nut. Sci., Univ of Shizuoka, 2. NHO, Kyoto Med Center, 3. Shizuoka Gen Hosp)

○Shihori Tanabe¹, Kazuhiko Aoyagi², Sabina Quader³, Horacio Cabral⁴, Ryuichi Ono⁵, Akihiko Hirose¹, Hiroshi Yokozaki⁶, Hiroki Sasaki⁷ (1. Div. Risk Assessment, Biol. Safety Res. Center, Natl. Inst. Health Sci., 2. Dept. Clin. Genomics, Natl. Cancer Center Res. Inst., 3. iCONM, 4. Grad. Sch. Engineer., Tokyo Univ. , 5. Div. Cel. Mol. Toxicol., Biol. Safety Res. Center, Natl. Inst. Health Sci., 6. Grad. Sch. Med., Kobe Univ., 7. Dept. Transl. Oncol., Natl. Cancer Center Res. Inst.)